Context Therapeutics Inc. (NASDAQ: CNTX) Stock Competitors & Peer Comparison
See CNTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CNTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CNTX | $0.37 | -3.99% | 33.8M | -0.77 | -$0.48 | N/A |
| VRTX | $508.34 | -1.55% | 129B | 26.70 | $19.03 | N/A |
| REGN | $784.85 | -0.58% | 80.9B | 17.20 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.32 | -0.55% | 61.6B | 89.38 | $11.08 | N/A |
| MRNA | $154.04 | -2.55% | 61.1B | -18.90 | -$8.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $190.95 | -3.04% | 40.6B | -21.64 | -$8.82 | N/A |
| RVMDW | $9.64 | -6.36% | 38.3B | -1.11 | -$8.82 | N/A |
| ONC | $350.84 | -0.74% | 37.5B | 61.77 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CNTX vs VRTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while VRTX trades at $508.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas VRTX's P/E ratio is 26.70. In terms of profitability, CNTX's ROE is -0.82%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CNTX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CNTX vs REGN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while REGN trades at $784.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas REGN's P/E ratio is 17.20. In terms of profitability, CNTX's ROE is -0.82%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CNTX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CNTX vs VRNA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CNTX's ROE is -0.82%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CNTX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CNTX vs ARGX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ARGX trades at $990.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ARGX's P/E ratio is 89.38. In terms of profitability, CNTX's ROE is -0.82%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, CNTX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
CNTX vs MRNA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MRNA trades at $154.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MRNA's P/E ratio is -18.90. In terms of profitability, CNTX's ROE is -0.82%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CNTX is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MRNA's competition here
Seagen Inc. (NASDAQ: SGEN)
CNTX vs SGEN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CNTX's ROE is -0.82%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CNTX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CNTX vs RVMD Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RVMD trades at $190.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RVMD's P/E ratio is -21.64. In terms of profitability, CNTX's ROE is -0.82%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, CNTX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CNTX vs RVMDW Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RVMDW trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, CNTX's ROE is -0.82%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, CNTX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
CNTX vs ONC Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ONC trades at $350.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ONC's P/E ratio is 61.77. In terms of profitability, CNTX's ROE is -0.82%, compared to ONC's ROE of +0.14%. Regarding short-term risk, CNTX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CNTX vs ALNY Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ALNY trades at $239.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ALNY's P/E ratio is 44.24. In terms of profitability, CNTX's ROE is -0.82%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CNTX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CNTX vs ROIV Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ROIV trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ROIV's P/E ratio is -37.84. In terms of profitability, CNTX's ROE is -0.82%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, CNTX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
CNTX vs INSM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, INSM has a market cap of 26B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while INSM trades at $120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas INSM's P/E ratio is -29.20. In terms of profitability, CNTX's ROE is -0.82%, compared to INSM's ROE of -1.11%. Regarding short-term risk, CNTX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
CNTX vs INCY Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while INCY trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas INCY's P/E ratio is 16.84. In terms of profitability, CNTX's ROE is -0.82%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CNTX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CNTX vs BNTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BNTX trades at $96.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BNTX's P/E ratio is -12.46. In terms of profitability, CNTX's ROE is -0.82%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, CNTX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
CNTX vs GMAB Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while GMAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas GMAB's P/E ratio is 26.18. In terms of profitability, CNTX's ROE is -0.82%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CNTX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CNTX vs UTHR Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while UTHR trades at $494.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas UTHR's P/E ratio is 17.70. In terms of profitability, CNTX's ROE is -0.82%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, CNTX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CNTX vs BGNE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CNTX's ROE is -0.82%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, CNTX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CNTX vs DNA-WT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CNTX's ROE is -0.82%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, CNTX is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CNTX vs JAZZ Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while JAZZ trades at $240.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, CNTX's ROE is -0.82%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, CNTX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CNTX vs NBIX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while NBIX trades at $146.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas NBIX's P/E ratio is 21.13. In terms of profitability, CNTX's ROE is -0.82%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CNTX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CNTX vs ASND Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ASND trades at $236.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ASND's P/E ratio is -97.82. In terms of profitability, CNTX's ROE is -0.82%, compared to ASND's ROE of +1.90%. Regarding short-term risk, CNTX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CNTX vs EXEL Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while EXEL trades at $58.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas EXEL's P/E ratio is 16.67. In terms of profitability, CNTX's ROE is -0.82%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, CNTX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CNTX vs SMMT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while SMMT trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas SMMT's P/E ratio is -15.94. In terms of profitability, CNTX's ROE is -0.82%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CNTX is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CNTX vs HALO Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while HALO trades at $112.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas HALO's P/E ratio is 20.98. In terms of profitability, CNTX's ROE is -0.82%, compared to HALO's ROE of +1.81%. Regarding short-term risk, CNTX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CNTX vs BBIO Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BBIO's P/E ratio is -17.81. In terms of profitability, CNTX's ROE is -0.82%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, CNTX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CNTX vs KRTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CNTX's ROE is -0.82%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CNTX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CNTX vs BMRN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BMRN's P/E ratio is 30.74. In terms of profitability, CNTX's ROE is -0.82%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, CNTX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CNTX vs MDGL Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MDGL trades at $531.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MDGL's P/E ratio is -41.52. In terms of profitability, CNTX's ROE is -0.82%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CNTX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CNTX vs TECH Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TECH trades at $72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TECH's P/E ratio is 37.30. In terms of profitability, CNTX's ROE is -0.82%, compared to TECH's ROE of +0.09%. Regarding short-term risk, CNTX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CNTX vs RNAM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CNTX's ROE is -0.82%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CNTX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CNTX vs AXSM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while AXSM trades at $207.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas AXSM's P/E ratio is -54.25. In terms of profitability, CNTX's ROE is -0.82%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, CNTX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CNTX vs TWST Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TWST trades at $166.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TWST's P/E ratio is -75.22. In terms of profitability, CNTX's ROE is -0.82%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CNTX is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TWST's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CNTX vs KRYS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while KRYS trades at $336.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas KRYS's P/E ratio is 42.19. In terms of profitability, CNTX's ROE is -0.82%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CNTX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check KRYS's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CNTX vs TXG Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TXG trades at $76.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TXG's P/E ratio is -129.83. In terms of profitability, CNTX's ROE is -0.82%, compared to TXG's ROE of -0.09%. Regarding short-term risk, CNTX is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CNTX vs KYMR Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while KYMR trades at $117.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas KYMR's P/E ratio is -36.80. In terms of profitability, CNTX's ROE is -0.82%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CNTX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CNTX vs RXDX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CNTX's ROE is -0.82%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CNTX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CNTX vs ARWR Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ARWR trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ARWR's P/E ratio is -29.55. In terms of profitability, CNTX's ROE is -0.82%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, CNTX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CNTX vs PTGX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PTGX trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PTGX's P/E ratio is 138.83. In terms of profitability, CNTX's ROE is -0.82%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, CNTX is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CNTX vs NUVL Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CNTX's ROE is -0.82%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CNTX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CNTX vs CRNX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CNTX's ROE is -0.82%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CNTX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CNTX vs IBRX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while IBRX trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas IBRX's P/E ratio is -8.74. In terms of profitability, CNTX's ROE is -0.82%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, CNTX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CNTX vs IMGN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CNTX's ROE is -0.82%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CNTX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CNTX vs TGTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TGTX trades at $56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TGTX's P/E ratio is 20.61. In terms of profitability, CNTX's ROE is -0.82%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, CNTX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TGTX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CNTX vs CYTK Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CYTK trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CYTK's P/E ratio is -9.53. In terms of profitability, CNTX's ROE is -0.82%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, CNTX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CNTX vs CAI Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CAI trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CAI's P/E ratio is 84.24. In terms of profitability, CNTX's ROE is -0.82%, compared to CAI's ROE of +0.19%. Regarding short-term risk, CNTX is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CNTX vs PCVX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PCVX's P/E ratio is -7.62. In terms of profitability, CNTX's ROE is -0.82%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, CNTX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CNTX vs BPMC Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CNTX's ROE is -0.82%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CNTX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CNTX vs APGE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas APGE's P/E ratio is -31.19. In terms of profitability, CNTX's ROE is -0.82%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CNTX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CNTX vs PRAX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PRAX trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PRAX's P/E ratio is -23.12. In terms of profitability, CNTX's ROE is -0.82%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, CNTX is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CNTX vs CERE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CERE's P/E ratio is -16.47. In terms of profitability, CNTX's ROE is -0.82%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CNTX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CNTX vs SYRE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while SYRE trades at $90.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas SYRE's P/E ratio is -46.28. In terms of profitability, CNTX's ROE is -0.82%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, CNTX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check SYRE's competition here
Abivax S.A. (NASDAQ: ABVX)
CNTX vs ABVX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ABVX trades at $105.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ABVX's P/E ratio is -55.06. In terms of profitability, CNTX's ROE is -0.82%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CNTX is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CNTX vs IMVT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while IMVT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas IMVT's P/E ratio is -13.10. In terms of profitability, CNTX's ROE is -0.82%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, CNTX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
CNTX vs MTSR Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CNTX's ROE is -0.82%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CNTX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CNTX vs IONS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while IONS trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas IONS's P/E ratio is -25.84. In terms of profitability, CNTX's ROE is -0.82%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CNTX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check IONS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CNTX vs BLTE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while BLTE trades at $170.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas BLTE's P/E ratio is -91.42. In terms of profitability, CNTX's ROE is -0.82%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, CNTX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
CNTX vs MRUS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CNTX's ROE is -0.82%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CNTX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CNTX vs ACLX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CNTX's ROE is -0.82%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CNTX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CNTX vs RYTM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RYTM trades at $97.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RYTM's P/E ratio is -31.42. In terms of profitability, CNTX's ROE is -0.82%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, CNTX is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RYTM's competition here
CG Oncology Inc. (NASDAQ: CGON)
CNTX vs CGON Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CGON trades at $74.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CGON's P/E ratio is -27.74. In terms of profitability, CNTX's ROE is -0.82%, compared to CGON's ROE of -0.25%. Regarding short-term risk, CNTX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CNTX vs RETA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RETA's P/E ratio is -66.29. In terms of profitability, CNTX's ROE is -0.82%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CNTX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CNTX vs CNTA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CNTX's ROE is -0.82%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CNTX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CNTX vs TVTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TVTX's P/E ratio is -139.47. In terms of profitability, CNTX's ROE is -0.82%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, CNTX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TVTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CNTX vs ORKA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ORKA trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ORKA's P/E ratio is -48.95. In terms of profitability, CNTX's ROE is -0.82%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, CNTX is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CNTX vs LGND Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while LGND trades at $283.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas LGND's P/E ratio is 31.12. In terms of profitability, CNTX's ROE is -0.82%, compared to LGND's ROE of +0.20%. Regarding short-term risk, CNTX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CNTX vs CDTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CNTX's ROE is -0.82%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CNTX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CNTX vs MIRM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MIRM trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MIRM's P/E ratio is -6.31. In terms of profitability, CNTX's ROE is -0.82%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, CNTX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MIRM's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CNTX vs SRRK Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while SRRK trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas SRRK's P/E ratio is -13.52. In terms of profitability, CNTX's ROE is -0.82%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, CNTX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
CNTX vs ABCM Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CNTX's ROE is -0.82%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CNTX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CNTX vs ISEE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CNTX's ROE is -0.82%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CNTX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CNTX vs PTCT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PTCT trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PTCT's P/E ratio is -28.06. In terms of profitability, CNTX's ROE is -0.82%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CNTX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CNTX vs CRSP Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CRSP trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CRSP's P/E ratio is -11.88. In terms of profitability, CNTX's ROE is -0.82%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, CNTX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CRSP's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CNTX vs DNTH Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while DNTH trades at $96.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas DNTH's P/E ratio is -23.33. In terms of profitability, CNTX's ROE is -0.82%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CNTX is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CNTX vs COGT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while COGT trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas COGT's P/E ratio is -14.93. In terms of profitability, CNTX's ROE is -0.82%, compared to COGT's ROE of -0.73%. Regarding short-term risk, CNTX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check COGT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CNTX vs APLS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas APLS's P/E ratio is 38.35. In terms of profitability, CNTX's ROE is -0.82%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CNTX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CNTX vs DFTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while DFTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas DFTX's P/E ratio is N/A. In terms of profitability, CNTX's ROE is -0.82%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, CNTX is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check DFTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
CNTX vs ERAS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ERAS trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ERAS's P/E ratio is -15.88. In terms of profitability, CNTX's ROE is -0.82%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, CNTX is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ERAS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CNTX vs EWTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while EWTX trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas EWTX's P/E ratio is -24.50. In terms of profitability, CNTX's ROE is -0.82%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, CNTX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
CNTX vs PBLS Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PBLS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PBLS's P/E ratio is -47.42. In terms of profitability, CNTX's ROE is -0.82%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, CNTX is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PBLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CNTX vs TERN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TERN's P/E ratio is -51.41. In terms of profitability, CNTX's ROE is -0.82%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CNTX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CNTX vs ACAD Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ACAD trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ACAD's P/E ratio is 12.29. In terms of profitability, CNTX's ROE is -0.82%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, CNTX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
CNTX vs IOVA Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while IOVA trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas IOVA's P/E ratio is -14.04. In terms of profitability, CNTX's ROE is -0.82%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, CNTX is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check IOVA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CNTX vs ADPT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ADPT trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ADPT's P/E ratio is -69.63. In terms of profitability, CNTX's ROE is -0.82%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, CNTX is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CNTX vs FOLD Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CNTX's ROE is -0.82%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CNTX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CNTX vs AKRO Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CNTX's ROE is -0.82%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CNTX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CNTX vs ALPN Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CNTX's ROE is -0.82%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CNTX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
CNTX vs MANE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MANE trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MANE's P/E ratio is -33.96. In terms of profitability, CNTX's ROE is -0.82%, compared to MANE's ROE of -0.38%. Regarding short-term risk, CNTX is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MANE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
CNTX vs TLX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while TLX trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas TLX's P/E ratio is 131.42. In terms of profitability, CNTX's ROE is -0.82%, compared to TLX's ROE of +0.07%. Regarding short-term risk, CNTX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check TLX's competition here
Opthea Limited (NASDAQ: OPT)
CNTX vs OPT Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas OPT's P/E ratio is -1.52. In terms of profitability, CNTX's ROE is -0.82%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CNTX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CNTX vs PRTC Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CNTX's ROE is -0.82%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CNTX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CNTX vs RLAY Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RLAY trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RLAY's P/E ratio is -12.00. In terms of profitability, CNTX's ROE is -0.82%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, CNTX is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CNTX vs MRTX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CNTX's ROE is -0.82%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CNTX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
CNTX vs CELC Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CELC trades at $80.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CELC's P/E ratio is -18.75. In terms of profitability, CNTX's ROE is -0.82%, compared to CELC's ROE of -3.51%. Regarding short-term risk, CNTX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CELC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
CNTX vs ABCL Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while ABCL trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas ABCL's P/E ratio is -23.39. In terms of profitability, CNTX's ROE is -0.82%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, CNTX is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CNTX vs CPRX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CPRX's P/E ratio is 12.30. In terms of profitability, CNTX's ROE is -0.82%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CNTX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CNTX vs XENE Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while XENE trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas XENE's P/E ratio is -8.46. In terms of profitability, CNTX's ROE is -0.82%, compared to XENE's ROE of -0.44%. Regarding short-term risk, CNTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for CNTX.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
CNTX vs AMLX Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while AMLX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas AMLX's P/E ratio is -22.63. In terms of profitability, CNTX's ROE is -0.82%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, CNTX is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check AMLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CNTX vs RYZB Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CNTX's ROE is -0.82%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CNTX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CNTX vs CBAY Comparison September 2026
Context Therapeutics Inc. (NASDAQ: CNTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTX stands at 33.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CNTX is priced at $0.37 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTX currently has a P/E ratio of -0.77, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CNTX's ROE is -0.82%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CNTX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for CNTX.Check CBAY's competition here